In a phase 3 trial, the agent reduces seizure frequency by up to 53% in treatment-resistant focal epilepsy, with rapid onset ...
Modified titration was associated with a 41% lower relative risk of ARIA-E than the standard dosing regimen. Topline results were announced from a phase 3b trial evaluating various dosing regimens of ...
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade ...
On March 18, 2026, MetaVia, Inc. (NASDAQ: MTVA) announced the approval of the clinical trial plan by the Institutional Review Board (IRB) at Clinical Pharmacology of Miami for the company’s Phase 1 ...
Single-nucleotide polymorphisms (SNPs) associated with outcomes in patients with localized and metastatic renal cell carcinoma (RCC). This is an ASCO Meeting Abstract from the 2017 Genitourinary ...
New research presented at the AACE 26th Annual Congress further validates that use of Glytec’s eGlycemic Management System ® eliminates barriers to adoption of basal bolus insulin and produces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results